Trainee (Evidence based medicines for rare (non oncology) diseases and regulatory pathways)
Selection procedure reference: EMA/TR/10468
Deadline for applications: 20 May 2024 23:59 CET
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in Amsterdam. It began operating in 1995. It is responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
The 2024 Traineeship programme is now open for applications until 20 May 2024 23:59 CET, with an intake on 1 October 2024.
About the traineeship programme
The Agency is looking for motivated, qualified recent graduates or students on an Erasmus+ or other programme or PhD students or Master's students (who posses a previous degree), who are interested in gaining experience and contribute to the Agency’s work for every patient in Europe. The purpose of a traineeship at the Agency is to perform tasks that are predominantly in the interest of the trainee’s training and principally serve to increase the trainee’s knowledge and to gain relevant experience.
Placement description
We are looking for a trainee in the Therapies for endocrine and cardiovascular diseases Office within the Human Medicines Division.
Specific objectives and projects
In Europe, the pharmaceutical legislation aims to promote the development of new medicines for rare diseases and foster early access to such treatment. The Therapeutic Areas Department works supporting the EMA Scientific Committees in enhancing structured assessment of benefit, harms and uncertainties in these medicines to improve communication to the public and an optimised use of the regulatory pathways.
During this traineeship, you will contribute to the design, data collection and analysis of a research project on the evidence based for non oncology medicines for rare diseases and regulatory pathways, will support Product Leads in coordinating the evaluation of initial marketing authorisation in this field, will see and will contribute to the regulatory and scientific activities of the ECV office.
Learning outcomes
You will have the opportunity to learn more on EMA's approach in approving medicinal products for non-oncology rare disease, develop expertise in designing, implementing and analyzing data from clinical studies, familiarize with regulatory requirements and different types of marketing authorization, agency processes and regulatory work
Eligibility criteria
To be eligible for consideration for this placement, you are required to:
- enjoy full rights as a citizen of a European Union Member State or Iceland, Lichtenstein and Norway;
- possess a university degree in biomedical sciences background, like medicine or pharmacy (minimum of three years or more) that must have been obtained within the last 12 months (graduated between 20 May 2023 and 20 May 2024) or be a university student on an Erasmus + or a similar programme or a PhD student or a Master's student with a previous fully finished degree in the areas mentioned before.
- a thorough knowledge of English (at least level C1) and good knowledge of other official EU language (at least B2) of the Common European Framework for Languages
For criteria 1 and 2, you will be required to provide proof in the application form and at the interview stage. Failing to present these documents may result in the disqualification from the procedure.
Additional skills
In addition to the eligibility criteria, you will also have
- Organisational skills.
- Communication skills (English writing and verbal).
- Analytical methods and research skills.
- Advanced skills of Microsoft Powerpoint, Excel and Statistical Software (e.g STATA) would be desirable.
Behavioural Competencies
You will demonstrate the following behavioural competencies:
- Communication skills
- Interpersonal skills
- Working with others
- Adaptability
- Research and analytical skills
- Learning and development
Expected selection timelines
Deadline for applications | 20 May 2024 23:59 CET |
---|---|
Assessments (remote) | From beginning of June 2024 to beginning of July 2024 |
Decision and offers | By end of July 2024 |
Placement start | 1 October 2024 |
Conditions of traineeship
The traineeship is offered for 10 months (1 October 2024 – 31 July 2025) and takes place at the Agency’s premises in Amsterdam with possibility for teleworking up to 40% of working time from The Netherlands and occasional teleworking from outside The Netherlands. Traineeships are offered for either full-time or part-time (80% or 50%) if combined with university studies.
The Agency pays a monthly stipend of €1,858.31 for a full-time traineeship (reduced accordingly for 80% or 50%) and a travel contribution upon joining the Agency.
Each trainee will have a mentor at the Agency who will guide the trainee through the programme.
The conditions of employment are stated in the Executive Decision on rules governing the traineeship programme at the EMA available here.
______________________________________________________________________________________________________
Domenico Scarlattilaan 6 - 1083 HS Amsterdam - The Netherlands
Telephone +31 (0)88 781 6000 - Email recruitment@ema.europa.eu
© European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged.
Job Segment:
Pharmaceutical, Oncology, Medical Research, Pharmacy, Science, Healthcare, Research